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To gain further knowledge on the preclinical phase of Alzheimer’s disease (AD), we
sought to characterize cognitive performance, neuroimaging and plasma-based AD
biomarkers in a cohort of non-demented adults with down syndrome (DS). The goal of
the down syndrome biomarker Initiative (DSBI) pilot is to test feasibility of this approach
for future multicenter studies. We enrolled 12 non-demented participants with DS
between the ages of 30–60 years old. Participants underwent extensive cognitive
testing, volumetric MRI, amyloid positron emission tomography (PET; 18F-florbetapir),
fluorodeoxyglucose (FDG) PET (18F-fluorodeoxyglucose) and retinal amyloid imaging.
In addition, plasma beta-amyloid (Aβ) species were measured and Apolipoprotein E
(ApoE) genotyping was performed. Results from our multimodal analysis suggest greater
hippocampal atrophy with amyloid load. Additionally, we identified an inverse relationship
between amyloid load and regional glucose metabolism. Cognitive and functional
measures did not correlate with amyloid load in DS but did correlate with regional FDG
PET measures. Biomarkers of AD can be readily studied in adults with DS as in other
preclinical AD populations. Importantly, all subjects in this feasibility study were able
to complete all test procedures. The data indicate that a large, multicenter longitudinal
study is feasible to better understand the trajectories of AD biomarkers in this enriched
population. This trial is registered with ClinicalTrials.gov, number NCT02141971.
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Introduction
The preclinical/asymptomatic stage of Alzheimer’s disease (AD) has become a target for therapeutic
intervention, requiring enriched populations to bemore intensively studied. Individuals with Down
Syndrome (DS) comprise the largest group with genetically determined AD, with a worldwide
population of about six million people. In March 2013, the Alzheimer’s Disease Cooperative
Study (ADCS) launched a pilot study named the Down Syndrome Biomarker Initiative (DSBI;
Ness et al., 2012). With the DSBI pilot, the ADCS’ goal was to initiate a longitudinal biomarker
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study similar to the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) in individuals with DS, who represent a population
highly enriched for developing AD. The ultimate aim of this
work is to aid the development of preventive therapies for the
dementia associated with both DS and AD, based on the apparent
common pathogenic role of beta amyloid (Aβ) in the two
conditions.
The tight link between genetic determinants of AD and
the overproduction of Aβ provides compelling support for
the amyloid cascade hypothesis and has been the focal
point in the development of disease-modifying drugs for
AD (for review, Sperling et al., 2011). We hypothesize
that disease-modifying treatments for AD and DS should
begin prior to the onset of cognitive symptoms to prevent
extensive neurodegeneration and thus necessitate a clear
understanding of biomarker changes throughout the course of
the disease.
The study of DS provides a unique opportunity to characterize
the preclinical changes associated with predisposition to AD.
DS, or trisomy 21, affects 400,000 people in the U.S. with
an incidence of 1/691 live births (Parker et al., 2010)
and is caused by meiotic non-disjunction, leading to an
extra copy of chromosome 21, on which the APP gene
resides.
Recent data suggest that AD biomarker changes in DS are
similar to those observed in familial and sporadic AD. For
example, studies demonstrate a six-fold increase in plasma
Aβ in individuals with DS as compared to age-matched non-
DS individuals (Schupf et al., 2001, 2007, 2010) and Aβ
positron emission tomography (PET) imaging data in DS are
consistent with AD patients (Sabbagh et al., 2011, 2015; Handen
et al., 2012). Furthermore, as seen in familial and sporadic
AD, presence of the Apolipoprotein E (ApoE) ε4 allele is
generally associated with greater accumulation of Aβ plaques
in the brains of adults with DS (Hyman et al., 1995; Lemere
et al., 1996). Presence of ApoE ε4 allele is also associated
with an earlier age of onset of dementia (Schupf et al.,
1996; Deb et al., 2000; Coppus et al., 2008; Prasher et al.,
2008).
Postmortem studies indicate that adults with DS have
a similar, prominent pattern of cerebral atrophy involving
the medial temporal lobe structures, as seen in the early
stages of AD (Hof et al., 1995; Teipel et al., 2004; Mullins
et al., 2013). Volumetric magnetic resonance imaging (MRI)
studies of age-related brain changes in DS demonstrate the
same pattern of hippocampal-specific atrophy observed in AD.
Furthermore, the hippocampal atrophy in DS correlates with
changes in memory measures (Krasuski et al., 2002; Beacher
et al., 2010). Hypometabolism on regional fluorodeoxyglucose
(FDG) PET also correlates with onset of dementia in older
adults with DS (Schapiro et al., 1992a,b; Pietrini et al.,
1997).
In this study, we collected structural MRI, Aβ PET, FDG
PET, retinal Aβ, plasma Aβ species, and cognitive performance
measurements in a cohort of 12 non-demented adults with DS
aged 30–60. Our goal was to establish feasibility of conducting a
biomarker-intensive study in adults with DS.
Materials and Methods
Study Design and Participants
The DSBI pilot enrolled 12 non-demented subjects for a 3-
year longitudinal study of AD biomarkers (see Table 1 for
Schedule of Events). The present analysis is restricted to the
baseline data. Four non-demented subjects were in each age
range: 30–40, 40–50 and 50–60. Inclusion criteria limited
enrollment to individuals having a chromosome karyotype
of DS due to Trisomy 21. Subjects were required to have
a caregiver, absence of other neurological and psychiatric
disorders, and be capable of and willing to perform study
procedures. Having a clinical diagnosis of dementia was
considered exclusionary as was presence of 6 months of
progressive cognitive or functional decline as per ICD-10
criteria (Sheehan et al., 2015). Exclusion of a diagnosis of
dementia was also based on absence of evidence of recent
deterioration in cognitive function found not secondary to
medical illness (e.g., hypothyroidism, sleep apnea) in conjunction
with absence of a significant decline in function over a
period of 6 months or more. The diagnosing neurologist was
experienced with dementia in DS and incorporated diagnostic
recommendations from the National Task Group on Intellectual
Disabilities and Dementia Practices (Moran et al., 2013). All
participants or their legal representatives provided written
informed consent before partaking in the study in accordance
with the regulations and approval of the ethics committee
TABLE 1 | Schedule of events for DSBI pilot.
Visit Screen/ YR1 YR2 YR3
BL (Comp)
Month 0 12 24 36
Study Procedures
Screening/administrative
Informed consent [/assent] x
Inclusion/exclusion criteria x
Medical history and demographics x
Safety assessments
Physical examination x x x x
Vital signs x x x x
Neurocog assessments
Scales, questionnaires, etc. x x x x
Clinical laboratory assessments
Hematology, Chemistry x x x x
Urinalysis x x x x
Pharmacogenomics (DNA)
ApoE x
Biomarkers (eg, plasma, serum
sample collection)
Plasma, serum collection x x x x
Imaging
Tau PET x x
Amyvid PET x x
FDG PET x x
vMRI x x x x
Retinal amyloid imaging x x x x
Ongoing subject review
Concomitant therapy x x x x
Adverse events x x x x
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at the University of California, San Diego, La Jolla, CA,
USA.
Procedures
Between March 2013 and January 2014, we collected data from
participants including plasma samples, neuropsychological
evaluations, neurological examination, ApoE genotyping,
volumetric MRI, amyloid PET, FDG PET, retinal Aβ
imaging, and clinical assessment. Subjects came for
five visits over a 5-week period for assessments to be
made. Events occured in the following order: visit 1:
neuropsychological and clinical assessment, neurological
examination; visit 2: Amyloid PET; visit 3: MRI and
blood draw; visit 4: FDG PET, visit 5: retinal Aβ
imaging.
Cognitive, Behavioral, and Functional Assessments
Cambridge Neuropsychological Test Automated Battery
(CANTAB). The CANTAB was used to assess cognition.
The CANTAB is a computerized touch-screen assessment
of neuropsychological function composed of a number of
tests (Luciana, 2003; Smith et al., 2013). The tests selected
from this battery for this study were as follows: motor
control (MOT): the subject is asked upon appearance of a
crossmark on the screen, to touch it as quickly and accurately
as possible using the index finger of their dominant hand.
This is essentially a practice routine to become skilled
with regards to touchscreen use. The outcome parameter
is median reaction time (RT): the subject is asked to hold
the index finger on the holding button on the button box
and keep it pressed until a circle on the screen lights up
and then touch that circle with the index finger as quickly
and accurately as possible. In the Simple condition, there
is only one possible circle that will light up (Simple RT).
In the five-choice condition, any of five circles can light
up (five-Choice RT). Paired associated learning (PAL):
the subject is shown 2–8 (max) distinct visual patterns,
each at one of eight positions inside of an octagon on the
screen. The task is to memorize which pattern occurred
where. After the memorization stage, each pattern is shown
in the center of the screen and the subject has then to
touch one of eight possible positions where the pattern first
occurred.
Repeatable Battery for the Assessment of Neuropsychological
Status (RBANS) was developed for the dual purposes of
identifying and characterizing abnormal cognitive decline
in the older adult and as a neuropsychological screening
battery for younger patients (Randolph et al., 1998). It is
a brief, individually administered test that can be used to
measure cognitive decline or improvement. The full battery
is composed of 12 subtests assessing the: immediate memory,
visuospatial abilities, language, attention and delayed memory.
In this study, seven subtests of the RBANS were used
to assess immediate and delayed memory, as well as the
language capacities (subtests: list learning, story memory, list
recognition, list recall, picture naming, semantic fluency, digit
span).
Vineland-II Adaptive Behavior Scale (VABS-II)
parent/caregiver interview form. The VABS-II measures
personal and social skills such as communication, daily
leaving skills, and socialization and will provide a composite
score reflecting an individual’s overall function. In addition,
the optional maladaptive behavior index could be used.
The survey interview form was administered to parents
or caregivers using a semi-structured interview format
(Sparrow and Havis, 2005).
Observer Memory Questionnaire-Parent Form (OMQ-PF).
The OMQ-PF is a 27-item questionnaire designed to ascertain
parents’ perceptions of the subject’s memory function. This
questionnaire is comprised of items inquiring about memory
function in everyday scenarios (Gonzalez et al., 2008).
Anxiety Depression and Mood Scale (ADAMS). The
ADAMS is a well validated, 28 item behavior-based informant
instrument designed to be used specifically with individuals
with developmental disabilities to assess anxiety, depression
and mood disorders (Esbensen et al., 2003). Points given for
each behavior the caregiver endorses. Subscales (5) include:
Manic/Hyperactive, Depressed Mood, Social Avoidance,
General Anxiety, Compulsive Behavior. The ADAMS possesses
a satisfactorily high alpha, with a mean alpha of 0.80 in each
of the 28 items. The mean item test-retest correlation is
0.789.
Cambridge Examination for Mental Disorders of Older
People with Down’s Syndrome and Others with Intellectual
Disabilities (CAMDEX-DS). Cognitive status was measured
using the Cambridge Cognitive Examination (CAMCOG), the
cognitive section of CAMDEX, a composite index of episodic
memory, orientation, language, attention, praxis and executive
function previously validated for use in DS (Hon et al., 1999).
The CAMCOG is appropriate for assessing cognitive function
in people with intellectual disability, unlike more standard tests
of cognitive function such as the Wechsler Adult Intelligence
Scales. The CAMCOG incorporates, and is highly correlated
with, the Mini Mental State Examination (MMSE; Blessed et al.,
1991).
Dalton Dyspraxia scale for Adults with DS: evaluates simple
sequences of voluntary movements expected to deteriorate with
the onset and progression of dementia in AD among persons
at all levels of premorbid intellectual disability. Participants
are given points for each task they are able to perform
(Dalton, 1992).
The Goodenough–Harris Draw-A-Person Test: brief paper
and pencil mental age test. This assessment system analyses 14
different aspects of a drawing done by the subject (such as specific
body parts and clothing) for various criteria, including presence
or absence, detail, and proportion. In all, there are 64 scoring
items. A standard score is recorded for the drawing, and a mental
age is assigned based on this score (Goodenough and Harris,
1950).
Biofluid Collection
Blood, (separated into plasma and serum), was collected to
accommodate the assay of the broadest range of the best
antecedent biomarkers/analytes. Blood samples were drawn in
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two lavender-capped EDTA tubes and one red-capped BD
tube. One lavender-capped tube was centrifuged at 3000 rpm
for 10 min to separate plasma for storage. Ten milliliter of
the plasma sample was aliquoted into barcoded polypropylene
vial and frozen at −80. The second blood tube was used
for serum extraction, which will be processed by allowing
the samples to clot at room temperature, spun as above
for plasma preparation, aliquoted and stored in barcoded
polypropylene tubes at −80. The third blood tube was
used for DNA isolation using Qiamp DNA blood maxi
kit (Qiagen). All biosamples were processed and stored
at the ADCS Biomarker Core using standard operating
procedure.
Plasma Aβ Analysis and Internal Standard
Banked plasma was assayed, quantified, and quality controlled
by the ADCS Biomarker Core using the MesoScale Validated
Aβ triplex (Aβ 38, 40, 42) according to the manufacturer
instructions. Each assay plate also included an internal standard
which provided a means for adjusting plate-to-plate variation
and assessing freezer storage effects, as previously described
(Donohue et al., 2014). To mitigate plate-to-plate variability,
plates were purchased in bulk and run consecutively.
Real Time PCR for Apolipoprotein E (ApoE)
Genotyping
Genotyping for ApoE alleles was performed using real time
PCR Restriction Fragment Length Polymorphism analysis by
the ADCS Biomarker Core according to standard operating
procedures. ApoE genotyping was performed using Applied
Biosystems TaqMan SNP Genotyping Assay (C_3084793_20 and
C_904973_10 corresponding to ApoE SNPs rs429358 and rs7412,
respectively). The assay was run on a Bio-Rad CFX96 Touch
Real Time PCR Detection System, using a cycling program of
98 C for 2 min. and 39 cycles of 98 C for 15 s and 62 C
for 45 s five positive controls for each genotype and one




The MRI protocol included series to assess for structural
pathology (T2-weighted fluid attenuated inversion recovery,
T2∗-weighted gradient recalled echo, and diffusion
weighted imaging) along with a series modeled on the
non-accelerated T1-weighted sequence from ADNI for
volumetric processing (3D inversion recovery prepared
spoiled gradient recalled imaging; inversion time 500,
flip angle 10, 1.25 mm × 1.25 mm in-plane resolution,
156 sagittal slices with 1.2 mm spacing). Scanning was
performed on a 1.5 Tesla GE Signa HDxt scanner, and
radiologist overread was performed on all scans to identify
any clinically significant incidental findings. NeuroQuant
image preprocessing and automated segmentation was used
to measure brain structure volumes (Brewer et al., 2009;
Kovacevic et al., 2009; Heister et al., 2011). Briefly, this
includes corrections for gradient non-linearities (Jovicich
et al., 2006) and intensity non-uniformity (Sled et al., 1998)
and application of probabilistic-atlas-based segmentation
to automate measurement of multiple brain regions (Fischl
et al., 2002). The procedure is cleared by the U.S. Food
and Drug Administration and the European Medicines
Agency for use in automating the identifying, labeling,
and quantifying the volume of segmental brain structures
identified on MR images (21 CFR 892.2050). To minimize
multiple comparisons, for analysis, a single measure of
medial temporal atrophy that comprises hippocampal
volume loss and temporal horn ex-vacuo dilatation,
‘‘Hippocampal occupancy (HOC),’’ was calculated as described
previously (Heister et al., 2011). This measure is simply
H/(H + T), where H is hippocampal volume and T is temporal
horn volume.
FDG PET
FDG PET procedures were based on those used in ADNI.1
Subjects were asked to fast for at least 6 h prior to the
scanning session. Subjects’ blood glucose was checked prior
to scanning and was required to be <180 mg/dL. After the
injection of 5 mCi of 18F-FDG, subjects were kept in a
quiet, dimly lit room with eyes and ears unoccluded for 30
min, after which they were placed in the Siemens EXACT
HR+ 961 PET tomograph (CTI, Knoxville, TN, USA), which
yielded 63 transverse sections spaced 2.43 mm apart with a
15.5 cm field of view (FOV) in 3D mode and 5 mm in-
plane spatial resolution full width at half maximum (FWHM).
Images were acquired at an angle parallel to the cantho-
meatal plane and reconstructed using a ramp filter (cut-off
frequency = 0.5 cycles/pixel) into 128 × 128 pixel images.
Each subject was placed in a headholder during scanning
to allow accurate positioning using a low-power neon laser.
Data were acquired as 6 × 5 min frames, followed by a
positron transmission scan. Frames were averaged and all images
were coregistered to the individual’s native space MRI. For
signal normalization, the brainstem was used as a reference
region.
Florbetapir F 18 PET
Subjects received IV injections of 10 mCi of Florbetapir F 18
and after 40 min of uptake, 10 min of emission data were
collected by the Siemens EXACT HR+ 961 PET tomograph
(CTI, Knoxville, TN, USA), which yielded 63 transverse sections
spaced 2.43, 3.5 mm apart with a 15.5 cm FOV in 3D mode,
with 4 mm in-plane spatial resolution (FWHM). Images were
acquired at an angle parallel to the cantho-meatal plane and
reconstructed using a Hann filter (cut-off frequency = 0.5
cycles/pixel) into 128 × 128 pixel images. Each subject was
placed in a headholder during scanning to allow accurate
positioning using a low-power neon laser. All PET scans were
supervised. Statistical analysis was performed as for FDG, except,
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TABLE 2 | Participant characteristics in DSBI feasibility study.
N (E4−) N (E4+) Total (N)
ApoE 6 6 12
Gender: F 6 4 10
Gender: M 1 1 2
Age 43.5 (9.8) 47.2 (7.4) 45.0 (9.8)
Educ. years:
0 0 1 1
12 2 5 7
18 4 0 4
There were six subjects who were ApoE4 positive and six who were ApoE4
negative. Average age was 45 (S.D. 9.8).
Retinal Aβ
The NeuroVision Retina HD is a fundus camera that is
substantially equivalent to the FDA approved cameras currently
utilized in clinical practice. In this procedure, a filter set
matched to the fluorescence characteristics of curcumin is
utilized for retinal amyloid plaque imaging in vivo. Quantitative
analysis of Aβ plaque number, area (µm2) and distribution
are performed from retinal images. For the acquisition,
the same exposure settings and the same gain values are
used for all images. The emission signals of Aβ plaques
stained with curcumin are compared to the background
signals in the retinal tissue, to determine signal-to-background
ratio.
At the visit, subjects had auto-fluorescence imaging
and curcumin fluorescence imaging of the right retina.
Patients were asked to take a standard over the counter
oral vitamin E supplement for each retinal amyloid imaging
visit, beginning at Day 1 and continuing through day 3 of
imaging. Patients were dosed with curcumin twice daily for
2 days; At Day 1, patients commenced taking oral curcumin.
On Day 2, subjects had another day of ingesting curcumin.
On Day 3, subjects had auto-fluorescence imaging, and
curcumin fluorescence imaging. NeuroVision calculated
the retinal amyloid index in a blinded fashion for each
subject.
Statistical Analysis
For cognitive, imaging analyses and fluid biomarker assessment,
ApoE4 carriers and non-carriers were compared in terms of their
age, educational level, clinical ratings, and neuropsychological
test scores using Wilcoxon and Pearson’s Chi-square tests.
We also estimated Spearman rank correlations for each
selected pairs of continuous measures. These correlation
analyses were group by variable type: (1) cognitive vs.
imaging; (2) cognitive vs. retinal and plasma; and (3) MRI
vs. PET. We controlled the false discovery rate within
each of these groups (Benjamini and Hochberg, 1995).
This pilot study is not well powered. All analyses should
be considered exploratory and any findings need to be
confirmed with larger sample sizes. The sample size of
n = 12 provides approximately 80% power to detect only
correlations larger than ρ = 0.84 with two-sided FDR α = 5%
and assuming 90% of null hypotheses are true. Similarly,
n = 6 subjects per ApoEε4 group provides approximately
80% power to detect only large standardized group differences
of δ = 2.66.
Results
All 12 participants completed all required testing. Tables 2
and 3 show demographic characteristics for the 12 non-
demented participants included in this study, grouped
by APoE4. Of the 12 subjects, 50% (n = 6) were ApoE4
carriers. All of the ApoEε4 non-carriers were female,
while four of the ApoEε4 carriers were female. These two
groups did not differ significantly in demographics, clinical
ratings, or neuropsychological test scores. All subjects were
TABLE 3 | Cognitive and functional performance summaries by ApoE4 geneotype.
N E4− E4+ Combined P-value
Direct testing
CAMCOG-DS 12 58.2 (23.4) 56.5 (20.3) 57.3 (20.9) 0.81
Goodenough-DAP 12 14.83 (9.47) 17.33 (2.73) 16.08 (6.78) 0.81
RBANS Composite 12 259.3 (30.1) 249.7 (47.1) 254.5 (38.0) 0.47
RBANS Digit span 12 4.67 (2.07) 3.33 (2.66) 4.00 (2.37) 0.27
RBANS List recall 12 14.67 (3.98) 11.83 (3.54) 13.25 (3.89) 0.18
RBANS Memory 12 50.00 (6.66) 49.50 (13.17) 49.75 (9.96) 0.68
RBANS Language 12 70.8 (19.9) 60.7 (16.3) 65.8 (18.2) 0.22
Delayed Memory 12 43.00 (3.79) 43.17 (7.76) 43.08 (5.82) 0.44
CANTAB-Total 12 87.5 (33.2) 109.0 (33.6) 98.2 (33.8) 0.29
Dalton Dyspraxia 12 205.7 (41.3) 177.7 (49.9) 191.7 (46.1) 0.31
Informant-based
ADAMS 12 17.8 (17.4) 17.8 (23.3) 17.8 (19.6) 0.81
Vineland-2 12 124.217 (32.9) 96.767 (24.5) 110.4 (31.2) 0.24
OMQ-PF 12 91.5 (27.1) 89.8 (27.3) 90.7 (26.0) 0.69
Higher score on all cognitive tests indicates better performance. The only exception is higher score on ADAMS, which indicates increased symptoms of anxiety, depression,
agitation. ADAMS, Anxiety Depression and Mood Scale; CAMCOG-DS, Cambridge Examination for Mental Disorders of Older People with Down’s Syndrome and
Others with Intellectual Disabilities-Cognitive scale; Goodenough DAP, Goodenough-Harris Draw a Person test; RBANS, Repeatable Battery for the Assessment of
Neuropsychological Status; (CANTAB), Cambridge Neuropsychological Test Automated Battery; OMQ-PF, Observer Memory Questionnaire (Parent Form).
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TABLE 4 | Amyloid PET and FDG PET with hippocampal volume and retinal amyloid index.
Subject Age Mental ApoE 4 Amyloid PET Grey matter FDG PET Average Average Retinal
age clinical read Amyloid PET clinical read Hippocampal Hippocampal amyloid index
(SUVr) volume (cm3) Occupancy (%)
DP06 37 9 E3-E3 Negative 0.938 Normal 3.52 73 1.63
DP01 32 7 E3-E3 Negative 0.97 Mildly hypo 3.12 78 2
DP07 34 7 E2-E4 Negative 0.988 Normal 3.37 75 2.47
DP08 39 5 E3-E3 Positive 1.054 Hypo 3.19 82 1.8
DP02 45 3 E2-E3 Positive 1.171 Hypo 2.99 45 2.2
DP12 45 6 E3-E4 Positive 1.176 Hypo 2.91 75 1.83
DP05 48 8 E3-E3 Positive 1.177 Hypo 3.47 77 1.68
DP11 47 7 E3-E4 Positive 1.245 Hypo 3.48 71 2.34
DP13 50 8 E3-E4 Positive 1.344 Hypo 3.14 60 1.58
DP04 55 6 E3-E4 Positive 1.385 Hypo 3.01 45 1.7
DP03 52 7 E3-E4 Positive 1.401 Hypo 3.25 51 2.2
DP09 60 7 E3-E3 Positive 1.457 Hypo 2.73 60 —
Areas with higher amyloid deposition have relative hypometabolism on FDG PET. The listing is sorted with respect to increasing grey matter amyloid PET signal.
amyloid positive, but to varying degrees. Table 4 provides
a line listing of some of the key neuroimaging variables
for each study participant sorted by posterior cingulate
gyrus (PCG) amyloid PET. Figure 1 demonstrates how
multimodal assessments are made across subjects in native
space.
Correlation Analyses
Figure 2 shows the correlation between key neuroimaging,
and age and cognition. Age was significantly associated with
florbetapir (AV45) uptake in the gray matter (r = 0.963,
p < 0.001) and thalamus (r = 0.595, p < 0.041), and HOC
(r = −0.662, p = 0.019). Florbetapir uptake in the gray matter
was also significantly correlated with OMQ PF (r = −0.769,
p = 0.005032). FDG uptake in the thalamus was significantly
correlated with CAMCOG, Digit Span, OMQ PF, RBANS, and
Vineland (all r > 0.6 and p < 0.01). HOC was correlated
with OMQ PF (r = 0.587, p = 0.049). Only the correlations
between FDG Thalamus and OMQ-PF; FDG Thalamus and
Vineland; and Florbetapir (AV45) Gray Matter and age were
significant at the 0.005 level (r = 0.776, r = 0.776, and r = 0.963
respectively).
Correlation Between Cognition, and Plasma Aβ
and Retinal Amyloid
Figure 3 shows the correlation between key neuroimaging,
and age and cognition. We found no significant
correlations between plasma or retinal amyloid measures
FIGURE 1 | Left: multimodal comparisons can be made in native space within individual subjects longitudinally. Right: Amyloid PET, FDG PET, and volumetric MRI
were successfully performed in adults with down syndrome (DS) to capture important structure-function relationships.
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FIGURE 2 | Correlations between cognitive and neuroimaging measures. The bold text indicates Spearman rank correlations (r) that are significant at the 0.05
level after false discovery rate adjustment. AV45 = 18F-florbetapir.
and with age or cognition (Figure 3); nor between
MRI and PET (Figure 4). We did find a significant
correlation between A beta 42 and age (r = 0.602, p =
0.038).
Correlation Between PET measures and HOC
We found a significant negative correlation between
Florbetapir (AV45) uptake in gray matter and HOC
(r = −0.615, p = 0.037). FDG uptake in thalamus and
HOC were positively correlated (r = 0.671, p = 0.020) see
Figure 4.
Retinal Amyloid Imaging
We imaged amyloid plaques in the retina of all subjects in
this small cohort, Figure 5. All subjects demonstrated amyloid
positivity.
Discussion
Although limited in sample size, this small pilot study provides
strong support for the feasibility of a multicenter longitudinal
AD biomarker study in adults with DS. Our findings also
show that prior to dementia onset, changes in volumetric MRI,
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FIGURE 3 | Correlations between cognitive measures, retinal amyloid and plasma biomarkers. None of the Spearman rank correlations (r) are significant at
the 0.05 level after false discovery rate adjustment.
amyloid PET and FDG PET and plasma are detectable and
consistent with preclinical AD in adults with DS. Adults with
DS had elevated levels of plasma Aβ1–42 concentrations and
plasma Aβ1–42:Aβ1–40 ratios. These findings are consistent
with previously published findings for individuals with DS
(Schupf et al., 2010). Consistent with previous autopsy studies,
most subjects demonstrated amyloid PET positivity reflecting
fibrillar amyloid plaque deposition.
We also find adults with DS can tolerate amyloid-β deposition
without significant effects on cognitive functioning. This has
been reported by others (Hartley et al., 2014) and likely
reperesents the preclinical stage of AD.
Study Strengths
We successfully studied AD biomarkers in all participants with
DS, who, in the absence of an effective prevention treatment,
are certain to develop symptoms of AD. With this cohort, we
confirm feasibility of a large-scale multicenter longitudinal study
designed to characterize trajectories of cognitive decline. The fact
that DS has native wild-type APP may make it more relevant
to studying biomarkers applicable to the general sporadic AD.
Additionally, we compared several different brain imaging and
fluid biomarkermeasurements, as well as exploratory biomarkers
such as retinal Aβ imaging, to characterize some of the earliest
biomarker changes associated with the predisposition to AD.
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FIGURE 4 | Correlations between PET and hippocampal occupancy (HOC). None of the Spearman rank correlations (r) are significant at the 0.05 level after
false discovery rate adjustment. AV45 = 18F-florbetapir.
FIGURE 5 | Representative retinal images from an adult with DS demonstrating positive amyloid plaques in DS. Note the orange-colored puncta. The
distribution in the vicinity of blood vessels is striking, pointing to a retinal manifestation of congophilic angiopathy.
Limitations and Issues of Interpretation
This study also has several limitations, including small sample
size, absence of longitudinal data, and uncertainty in the extent
to which our findings are generalizable to other causes of
late-onset AD. Although the retinal amyloid findings should
be regarded as exploratory, the uncorrected significance levels,
bilateral pattern, and resemblance to the pattern reported
previously in patients with AD reduce the likelihood that they
are attributable to the type I error associated with multiple
regional comparisons. Although our findings are currently
limited to DSBI pilot participants, we have sought to harmonize
our biomarker measurements and undertake biological fluid
assays in the same laboratory used by investigators in the
study of other DS cohorts (LonDowns and Fundació Catalana
de Síndrome de Down), thus providing complementary data
and converging evidence in the preclinical study of AD in DS
patients.
Additional studies are needed to clarify several issues: the
extent to which the structural and functional abnormalities
identified in young adults with DS at genetic risk for AD
precede Aβ plaque deposition; whether these changes are
neurodegenerative or developmental; whether or not there is any
cerebral fibrillar Aβ deposition in young adults with DS.
Conclusion
Adults with DS have volumetric MRI, Aβ PET, FDG PET
and retinal Aβ changes, along with plasma biomarker findings
consistent with Aβ1–42 overproduction. This study shows
some of the earliest known AD biomarker changes in adults
with DS and underscores the need for studies to clarify the
earliest brain changes associated with the predisposition to
AD. We have recently added Tau PET imaging to the set
of biomarkers assessed in this cohort. Under the auspices
of the DSBI pilot, we are continuing to characterize the
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age-related trajectory of biomarker changes associated with
preclinical AD to set the stage for the first clinical trial of an
anti-Aβ therapy in the preclinical treatment of AD in adults
with DS.
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